N,O-Dialkyl deoxynojirimycin derivatives as CERT START domain ligands.


Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 01 2020
Historique:
received: 13 09 2019
revised: 17 10 2019
accepted: 30 10 2019
pubmed: 24 11 2019
medline: 23 1 2021
entrez: 24 11 2019
Statut: ppublish

Résumé

Dysregulation of the ceramide transport protein CERT is associated to diseases such as cancer. In search for new CERT START domain ligands, N-dodecyl-deoxynojirimycin (N-dodecyl-DNJ) iminosugar was found to display, as a ceramide mimic, significant protein recognition. To reinforce the lipophilic interactions and strengthen this protein binding, a docking study was carried out in order to select the optimal position on which to introduce an additional O-alkyl chain on N-dodecyl-DNJ. Analysis of the calculated poses for three different regioisomers indicated an optimal calculated interaction pattern for N,O3-didodecyl-DNJ. The two most promising regioisomers were prepared by a divergent route and their binding to the CERT START domain was evaluated with fluorescence intensity (FLINT) binding assay. N,O3-didodecyl-DNJ was confirmed to be a new binder prototype with level of protein recognition in the FLINT assay comparable to the best known ligands from the alkylated HPA-12 series. This work opens promising perspectives for the development of new inhibitors of CERT-mediated ceramide trafficking.

Identifiants

pubmed: 31757669
pii: S0960-894X(19)30761-9
doi: 10.1016/j.bmcl.2019.126796
pii:
doi:

Substances chimiques

Ceramides 0
Ligands 0
deoxynojirimycine 0
1-Deoxynojirimycin 19130-96-2
CERT1 protein, human EC 2.7.1.-
Protein Serine-Threonine Kinases EC 2.7.11.1
Glycoside Hydrolases EC 3.2.1.-
Glucosamine N08U5BOQ1K

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126796

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Tessa Castellan (T)

SPCMIB, UMR5068 CNRS-Université Paul Sabatier-Toulouse III, 118 route de Narbonne, Toulouse F-31062, France.

Cécile Santos (C)

SPCMIB, UMR5068 CNRS-Université Paul Sabatier-Toulouse III, 118 route de Narbonne, Toulouse F-31062, France.

Frédéric Rodriguez (F)

SPCMIB, UMR5068 CNRS-Université Paul Sabatier-Toulouse III, 118 route de Narbonne, Toulouse F-31062, France.

Mathieu L Lepage (ML)

Laboratoire d'Innovation Moléculaire et Applications (LIMA), Univ. de Strasbourg|Univ. de Haute-Alsace|CNRS (UMR 7042), Equipe de Synthèse Organique et Molécules Bioactives (SYBIO), ECPM, 25 Rue Becquerel, 67000 Strasbourg, France.

Yan Liang (Y)

Laboratoire d'Innovation Moléculaire et Applications (LIMA), Univ. de Strasbourg|Univ. de Haute-Alsace|CNRS (UMR 7042), Equipe de Synthèse Organique et Molécules Bioactives (SYBIO), ECPM, 25 Rue Becquerel, 67000 Strasbourg, France.

Anne Bodlenner (A)

Laboratoire d'Innovation Moléculaire et Applications (LIMA), Univ. de Strasbourg|Univ. de Haute-Alsace|CNRS (UMR 7042), Equipe de Synthèse Organique et Molécules Bioactives (SYBIO), ECPM, 25 Rue Becquerel, 67000 Strasbourg, France.

Philippe Compain (P)

Laboratoire d'Innovation Moléculaire et Applications (LIMA), Univ. de Strasbourg|Univ. de Haute-Alsace|CNRS (UMR 7042), Equipe de Synthèse Organique et Molécules Bioactives (SYBIO), ECPM, 25 Rue Becquerel, 67000 Strasbourg, France.

Yves Génisson (Y)

SPCMIB, UMR5068 CNRS-Université Paul Sabatier-Toulouse III, 118 route de Narbonne, Toulouse F-31062, France.

Cécile Dehoux (C)

SPCMIB, UMR5068 CNRS-Université Paul Sabatier-Toulouse III, 118 route de Narbonne, Toulouse F-31062, France.

Stéphanie Ballereau (S)

SPCMIB, UMR5068 CNRS-Université Paul Sabatier-Toulouse III, 118 route de Narbonne, Toulouse F-31062, France. Electronic address: ballereau@chimie.ups-tlse.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH